XBiotech Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; the filing also reports fourth-quarter results. XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies. It has no approved products and relies on research and development, contract manufacturing and clinical services.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $18.4 million | $44.0 million |
| Gross profit / gross margin | $12.6 million / 68.4% | $9.4 million / 21.5% |
| Research and development expense | $28.3 million | $9.5 million |
| General and administrative expense | $9.4 million | $18.2 million |
| Operating loss | $25.1 million | $18.3 million |
| Net loss | $17.4 million ($0.58/share) | $11.2 million ($0.36/share) |
| Cash and cash equivalents at year-end | $237.0 million | $237.4 million |
| Operating cash flow | $69.4 million provided | $65.1 million used |
FY2021 revenue was almost entirely manufacturing revenue of $18.0 million; clinical-trial services contributed $0.4 million. The operating cash inflow included receipt of the $75 million Janssen escrow payment, so it should not be read as recurring operating cash generation. Cash declined only $0.4 million during the year, after a $75 million dividend and $3.5 million of property and equipment spending. The company reported $5.8 million of total liabilities, no debt, and $246.9 million of current assets against $3.5 million of current liabilities.
The $8.0 million income-tax benefit primarily reflected an estimated $9.5 million refund of prior-year Canadian taxes through loss carryback. FY2021 fourth-quarter net loss was $6.5 million, or $0.21 per share.
Changes versus prior periods
- Revenue fell 58% from FY2020, chiefly because clinical-trial service revenue dropped from $26.0 million to $0.4 million; manufacturing revenue remained $18.0 million.
- Gross profit increased to $12.6 million from $9.4 million as cost of goods sold declined to $5.8 million from $34.5 million. The revenue and cost mix changed substantially between periods.
- R&D expense rose to $28.3 million from $9.5 million; management cited expense classification changes related to Janssen as well as higher costs. G&A expense fell 48%, primarily due to lower share-based compensation, tender-offer-related fees and other costs.
- Net loss widened to $17.4 million from $11.2 million. FY2019’s $668.6 million net income included the exceptional Janssen transaction gain and is not a recurring comparison.
- Cash remained broadly stable year over year. The company received the remaining $75 million Janssen escrow in 2021 and paid a $75 million dividend, approximately $2.50 per share. Management does not expect comparable dividends in the foreseeable future.
Outlook, business developments and risks
- In 2021, XBiotech advanced an anti-IL-1α candidate into an oncology clinical study for pancreatic cancer, started a rheumatology clinical program after filing INDs, and filed an IND for a different anti-IL-1α antibody in cardiovascular medicine.
- A February 2022 agreement with a Janssen-related company extends bermekimab manufacturing through December 2023 for total payments of approximately $4.7 million. Management expects contract revenue to offset part of R&D operating costs; it does not expect manufacturing revenue under this agreement after its expiry.
- Management expects significant operating losses to continue and increase as development advances, with G&A costs also potentially rising amid inflation. It stated that year-end cash should fund operations for at least 12 months from the March 15, 2022 report date and support several clinical milestones.
- XBiotech is developing multiple anti-IL-1α antibodies for indications outside dermatology; its Janssen arrangements restrict further development of anti-IL-1α antibodies in dermatology. Janssen milestone payments could total up to $600 million, but depend on Janssen’s decisions, regulatory approvals and other conditions; receipt is not assured.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, patient enrollment, competition, COVID-19 effects on trials and supply chains, dependence on contract revenue, and the need for possible additional financing. The company has no product-sales revenue and may never achieve sustained profitability.
- The company reported no material legal proceedings. Ernst & Young issued an unqualified opinion on the financial statements; the auditor was not engaged to opine on internal control effectiveness. Management reported effective disclosure controls and internal control over financial reporting.
Investor verification points
- Confirm the status, enrollment, timelines and next data milestones for the oncology, rheumatology and cardiovascular programs.
- Review the detailed terms, payment schedule and performance obligations of the 2022 Janssen manufacturing agreement, and whether any further milestone payments become probable.
- Assess cash runway using recurring operating costs and cash flows, excluding the one-time escrow receipt and considering the end of Janssen manufacturing revenue in 2023.
- Verify the basis and timing of the estimated Canadian tax refund and monitor tax positions and carryforwards.
- Track the impact of development spending, facility expansion, share-based compensation and potential financing on cash and shareholder dilution.